Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Depression? You depressed Regis?
Depression Bear Market Sky high Inflation
Back under $2. Darn. Thought sub $2 was far beyond us by now. No market confidence.
Nice pop PM
Looks like the social media freaks jumped on it early and bailed out just as quick when the hammer came down towards the open. Great volume and NY AMex gives it some much better exposure for down the road
Now its back to waiting for the FDA
KNWN changed to KNW. Moved to the NYSE AMEX from the OTC:
https://otce.finra.org/otce/dailyList?viewType=Deletions
Any idea what the ipo price is tomorrow?
Yeah but IPO Joe crew will be in this stock for the uplisting
I got an email from the underwriter (Boustead) yesterday indicating that the 3M shares were available for purchase in the IPO and that the IPO window would close on Wed (9/14) and KNWN would appear on the NYSE on Thu (9/15). I'm guessing that there were administrative delays, either from Boustead or from the NYSE. Having a week to set up and fund an account with Boustead in order to purchase shares in the IPO subscription seems pretty tight.
Offering pushed back to late next week
Anyone hearing why
Ive been a shareholder and involved with KNWN for many years. I sold in the 4's long time ago and bought back in the low 2's
If the share price makes a crazy run, of course Im gonna dump because it will eventually come back down.
Regarding negative posts, thats a simple explanation. The great, great majority of OTC stocks are over valued junk, so the natural result is negative opinions. Most of mine are formed from real DD and many years experience in financing and the capital markets
I have read may of your other posts and you seem to be negative on most boards. Don't invest in KNWN if you don't believe it will be a momentum play. It doesn't matter in the near team what the offering price is. If this is a momentum play like JZ or ATXG , it could rocket for a few days before coming back.
Yes, I saw that big move up.
However, that move came pre-offering, where 3m more shares will be added to the float with a $2(?) cost basis..
Curious to see what happens.
Well, that was quick// Maybe theyre going to price this higher than $2...
I wouldn't be so sure about that. avg volume is only 38k Volume now is over 400k. Its moved up almost $1 on only 400k.
Float too big for the reddit/twits freaks to jump on and run it
Whats the immediate catalyst for a big move up once listed?
KNWN Moving up nicely ahead of uplilsting. When it moves to NYSE this could go parabolic (people seem to like to say that)....anyway, it could be a pretty big day tomorrow or Thursday.
Where you seeing this? Nothing listed on finra site.
KNWN uplisting to NYSE this week. KNW will be the new ticker. This should absolutely take off. Price is already climbing. Uplisting should be Wednesday or Thursday.
Free Writing Prospectus
https://newsfilter.io/a/0bcf108530f44a5584dd8261b6b66147
https://mailchi.mp/d0a997b08c4f/know-labs-provides-update-on-irb-approved-internal-trial-of-non-invasive-glucose-monitoring-technology?e=fe4a97048d
Great News KNWN. Naked shorts beware
This Company Reports Moving Toward FDA Approval To Provide Pain-Free Diabetes Monitoring
https://www.benzinga.com/general/biotech/22/08/28431449/this-company-reports-moving-toward-fda-approval-to-provide-pain-free-diabetes-monitoring
Know Labs Inc.
KNWN
, an emerging developer in noninvasive medical diagnostics, focuses on developing its proprietary spectroscopic technologies using the electromagnetic spectrum. The goal is to accurately identify and measure a wide range of organic and inorganic materials, molecules and compositions of matter.
Know Labs’ technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. It refers to its technology as Bio-RFID™, which can be integrated into various wearable, mobile or bench-top devices. The company’s patented and patent-pending technology makes it possible to effectively identify and monitor analyses that could only previously be performed by invasive, expensive and time-consuming lab-based tests.
The first application of its Bio-RFID technology will reportedly be in a product marketed as a noninvasive glucose monitor, giving the user real-time information on blood glucose levels.
Know Labs’ leadership says it's confident it will be the first company to bring an FDA-cleared noninvasive glucose monitoring device to market. Know Labs is conducting a 200-person internal clinical trial of Bio-RFID, which will help the company refine its algorithm and demonstrate Bio-RFID’s accuracy in a large population... Previous internal tests demonstrated Bio-RFID has accuracy on par or better than currently available solutions, which is an important step toward FDA submission.
For more information on Know Labs Inc., visit knowlabs.co.
KNWN FOUNDER RON ERICKSON STRIKES AGAIN
https://www.forbes.com/sites/forbestechcouncil/2022/08/08/how-noninvasive-diagnostic-technology-can-revolutionize-medicine/?sh=4e4f61dc2af3
How Noninvasive Diagnostic Technology Can Revolutionize Medicine
https://www.nytimes.com/2022/08/05/technology/ai-sentient-google.html?unlocked_article_code=AAAAAAAAAAAAAAAACEIPuonUktbfqYhkQFUbBibJUNMnqBqCgvfeh7U9w2TzKjSURDBeiusSBIeE9gHNea9nLZMV7giseeVgYvUpVeAgiahWJVBsQA2l5ZCNlspff3U_7Nu5D25zgsqUA_UyoTGwKzXmce52z-KxskjWOXL4G_CKiQ1XLwxvpJBifF2vyCZIkv-DSrgpr4E4ifQxBZl6RiMCbT2Iu5ToCRZ-PdaHZ3LM-1V8GrEZCXyIw4nqu_9Xex5SCFnGUHp1_W43jdhdM9gRN6z1RAUyBbQDVlpk-7x6Rs7m7Bu8iw&referringSource=articleShare
Phil and experienced tech entrepreneur who was helping to build a new company, Know Labs. Wonder who that can be?
Great article.
Thank you!
Know Labs, Inc.
3,000,000 Shares of Common Stock
This is a firm commitment public offering. We are offering 3,000,000 shares of our common stock, par value $0.001 per share. We currently estimate that the public offering price will be $2.00 per share.
Our common stock is presently traded on the OTC Market Group Inc.’s QB tier, or OTCQB, under the symbol “KNWN.” We plan to apply to have our common stock listed on NYSE American under the symbol “KNW,” which listing is a condition to this offering. No assurance can be given that our application will be approved. On July 26, 2022, the last reported sales price for our common stock as quoted on the OTCQB was $2.14 per share.
https://app.quotemedia.com/data/downloadFiling?webmasterId=102291&ref=116852046&type=HTML&symbol=KNWN&companyName=Know+Labs+Inc&formType=S-1&formDescription=Registration+statement+under+Securities+Act+of+1933&dateFiled=2022-07-29&CK=1074828
Link?...........
Our patience will soon pay off. Congratulations to all who held through thick and thin.
Years and Years of negative comments. Makes little sense.
You knew nothing. Thank you for finally coming clean. Carry on.
KNOW will be uplisting to the NYSE per their latest release.
OK, I will commit to stop being so negative about these guys. My apologies. I do hold a substantial position and am truly pulling for them.
Lol. Just ignore that balance attachment
KNWN's form 8-K of today
(https://www.sec.gov/ix?doc=/Archives/edgar/data/1074828/000165495422010283/knwn_8k.htm)
Has an amazing exhibit called "Four Page S-1 Product Presentation Insert - Filed herewith" with some new amazing product info!!!
https://www.sec.gov/Archives/edgar/data/1074828/000165495422010283/knwn_ex991.htm
Class 1 device.
Does anyone know the class of the Know Labs’ medical devices, and what route will they take to market approval?
Does anyone know the class of the Know Labs’ medical devices, and what route will they take to market approval?
I see Mr. Takesako is up for re-election to the Board of Directors. Guess we will see if his insider’s activities affect his selection. But is it not a big deal with him owning only 0.13%? https://money.cnn.com/quote/shareholders/shareholders.html?symb=KNWN&page=4&duration=365
FYI July 2022 Know Labs Inc. Investors Presentation
https://www.knowlabs.co/_files/ugd/23f159_ec23baa41800460cab500921c11e2beb.pdf
Can only think of personal reasons for him. All other insiders would be nuts to see if they think the stock will risk and the company will uplist then their shares would be marginable ie they could borrow against their holdings. So it must be in their self interest to advance the company.
I still want to know why Ichiro Takesako is the only insider selling KNWN? Is this a ploy because other insiders are buying Ronald Erickson, William Owens, Peter Conley, and Leo Trautwein. I know there is a shortfall between Mr. Takesako's selling and what the others bought. But why is only one insider selling?
Time to clean up the misinformation being proffered by a few posters on this board.
From KNWN management on their discord channel:
Sorry for the delay. First of all, thanks for all the contributions. Second, we continue to test daily. For confidentiality reasons, we can't share details on the tests. Any material event will be communicated through press release and our social medial channels, including our newsletter. Lastly, it is time to start focusing on what happens once the internal trials are completed. We have been preparing for that, which includes refining the regulatory strategy, building the package of documents for pre-sub meeting, conducting 3rd party tests that prove compliance to safety requirements, and the list goes on and on. Rest assured, the team has been busy.
Slunj- when did they extend the deadline for their IRB study? Thanks in advance.
The talk regarding deadlines is ridiculous. April 15, tax day, is a deadline for filing your taxes or an extension. When you are developing technology that has never been created before the very notion of deadlines is antithetical to the inventive process and the refinement of the invention for commercialization. The Company makes its best estimates. Regarding RMacchio “No soup for you!”
What deadline was missed? Please provide a link.
Laughing to myself as I think of what my customer's reactions would be if I told them that I gave them a date that I expected to miss. You and I are cut from a different mold.
Followers
|
75
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3547
|
Created
|
10/19/08
|
Type
|
Free
|
Moderators |
About Know Labs, Inc.
Know Labs, Inc. (f/k/a Know Labs Incorporated) is a public company whose shares trade under the stock symbol “KNWN.” The company’s technology directs structured light or radio waves through a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests. For more information on Know Labs, visit the company’s website at http://bit.ly/knowlabs
Overview
Historically, the Company focused on the development of our proprietary ChromaID technology. Using light from low-cost LEDs (light emitting diodes) we map the color of substances, fluids and materials and with our proprietary processes we can authenticate, identify and diagnose based upon the color that is present. The color is both visible to us as humans but also outside of the humanly visible color spectrum in the near infra-red and near ultra-violet and beyond. Our ChromaID scanner sees what we like to call “Nature’s Color Fingerprint.” Everything in nature has a unique color identifier and with ChromaID we can see it, and identify, authenticate and diagnose based upon the color that is present. Our ChromaID scanner is capable of uniquely identifying and authenticating almost any substance or liquid using light to create, record and detect its unique color signature. We will continue to develop and enhance our ChromaID technology and extend its capacity. More recently, we have focused upon extensions and new inventions that are derived from and extend beyond our ChromaID technology. We call this technology Bio-RFID. The rapid advances made with our Bio-RFID technology in our laboratory have caused us to move quickly in to the commercialization phase of our Company as we work to create revenue generating products for the marketplace.
ChromaID and Bio-RFID: Foundational Platform Technologies
Our ChromaID and Bio-RFID technologies provide a platform upon which a myriad of applications can be developed. As platform technologies, they are analogous to a smartphone, upon which an enormous number of previously unforeseen applications have been developed. ChromaID and Bio-RFID technologies are “enabling” technologies that bring the science of electromagnetic energy to low-cost, real-world commercialization opportunities across multiple industries. The technologies are foundational and, as such, the basis upon which the Company believes a significant business can be built.
As with other foundational technologies, a single application may reach across multiple industries. The ChromaID technology can, for example effectively differentiate and identify different brands of clear vodkas that appear identical to the human eye. By extension, this same technology can identify pure water from water with contaminants present. It can provide real time detection of liquid medicines such as morphine that have been adulterated or compromised. It can detect if jet fuel has water contamination present. It could determine when it is time to change oil in a deep fat fryer. These are but a few of the potential applications of the ChromaID technology based upon extensions of its ability to identify different clear liquids.
Similarly, the Bio-RFID technology can non-invasively identity the presence and quantity of glucose in the human body. By extension, there may be other molecular structures which this same technology can identity in the human body which, over time, the Company will focus upon. They may include the monitoring of drug usage or the presence of illicit drugs. They may also involve identifying hormones and various markers of disease.
The cornerstone of a company with a foundational platform technology is its intellectual property. We have pursued an active intellectual property strategy and have been granted 12 patents. We currently have 20 patents pending. We possess all right, title and interest to the issued patents.
About Our Team
Phil Bosua
Chief Executive Officer
Phil Bosua is an internationally recognized inventor and innovator. His expertise in lighting lead him to found LIFX (www.lifx.com) where he created the world’s first commercial smart light bulb. The 2012 crowdsourcing launch of his smart light bulb raised $1.3 million in six days and attracted $12 million in funding from Sequoia Capital (www.sequoiacap.com). This groundbreaking invention earned him the prestigious Edison Gold Award (www.edisonawards.com) presented by Elon Musk to innovators who create products that have a positive impact on the world. Bosua also founded RAAI, Inc., where he continued his innovative creation of new uses of light. Bosua said, “The time I have spent in the Visualant lab working on advancing their technology has been some of the most scintillating moments of my career. Ron Erickson and Visualant have provided support to allow me and the lab team to explore new products and discover new technologies. I’m excited by the technology platform we are creating, knowing that it will benefit millions of people around the world and be equally as good for our shareholders.”
LinkedIn: http://bit.ly/2yeBNR9
Press Release: http://bit.ly/2HJRZsJ
Ronald P. Erickson
CFO, President and Chairman of the Board.
Mr. Erickson has been a director and officer of the Company since April 24, 2003. He currently serves as the Company's Chairman, Chief Executive Officer and President. He was appointed to the positions of CEO and President on November 10, 2009. Earlier, he was appointed President and Chief Executive Officer of the Company on September 29, 2003, and resigned from this position on August 31, 2004 at which time he was appointed Chairman of the Board. A seasoned executive with more than 30 years of experience in the high technology, telecommunications, micro-computer, and digital media industries, Mr. Erickson was the founder of Know Labs. In addition to his Know Labs responsibilities he also serves as Chairman of ivi, Inc. a streaming media company and eCharge Corporation an Internet based transaction processing company. He is formerly Chairman, CEO and Co-Founder of Blue Frog Media, a mobile media and entertainment company; Chairman, CEO and Co-founder of GlobalTel Resources, a provider of telecommunications services; Chairman, Interim President and CEO of Egghead Software, Inc. the large software reseller where he was an original investor; Chairman and CEO of NBI, Inc.; and Co-founder of MicroRim, Inc. the database software developer. Earlier, Mr. Erickson practiced law in Seattle and worked in public policy in Washington, DC and New York, NY. Additionally, Mr. Erickson has been an angel investor and board member of a number of public and private technology companies. Mr. Erickson has a BA from Central Washington University, a MA from the University of Wyoming and a JD from the University of California, Davis. He is licensed to practice law in the State of Washington and the District of Columbia.
LinkedIn: http://bit.ly/2t2oE7T
Bill Owens
Know Labs Board of Directors
Admiral Owens is currently the co-founder and executive chairman of Red Bison Advisory Group, a company which identifies opportunities with proven enterprises in China, the Middle East, and the United States and creates dynamic partnerships focusing on: natural resources (oil, gas and fertilizer plants), real estate, and information and communication technology. Most recently, he was the chairman of the board of CenturyLink Telecom, the third largest telecommunications company in the United States and was on the advisory board of SAP USA. Owens serves on the board of directors at Wipro Technologies and is a director of the following private companies: Humm Kombucha, a beverage company and Versium. Owens is on the advisory board of the following private companies: Healthmine, Platform Science, Sarcos, Sierra Nevada Corporation, and Vodi. Owens is on the board of trustees at EastWest Institute, Seattle University, and an advisor to the Fiscal Responsibility Amendment (CFFRA) Association which aims to establish a balanced budget amendment to the US Constitution. He is also a member of the Council of Foreign Relations.
LinkedIn: http://bit.ly/2K6DJwx
Press Release: http://bit.ly/2JzG7PO
CONTACT US
Know Labs, Inc.
Jordyn Theisen, Ph. 206-903-1351
Email: jordyn@knowlabs.co
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/KNWN/company-info
Ticker: $KNWN
OTC Market Tier: OTCQB
CIK code: 0001074828
Company name: Know Labs, Inc.
Company website: http://bit.ly/knowlabs
Incorporated In: NV, USA
##### recent news/filings
Latest filings: http://www.otcmarkets.com/stock/KNWN/filings
Latest financials: http://www.otcmarkets.com/stock/KNWN/financials
Latest news: http://www.otcmarkets.com/stock/KNWN/news - http://finance.yahoo.com/q/h?s=KNWN+Headlines
Corporation WIKI:
Corporate website internet archive: http://bit.ly/knowlabs
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |